United InnoMed (Shanghai)^®(United InnoMed^®)Completed a new round of financing exceeding 100 million yuan. This round of financing was led byLongpan InvestmentAndDaoTong InvestmentCo-led by, Yingle Health Fund and Tianrui Fengnian followed up, existing shareholdersLilly Asia FundContinued support, with Dianshi Capital serving as the exclusive financial advisor. This round of financing will mainly be used for the research and development and registration clinical trials of several core products under development by the company.

Founder andCEODr. Wang Li, is a national-level overseas high-level talent, deeply engaged in Class III active implantable heart failure andCRMField30Years. Formerly served as Chief Scientist at Medtronic headquarters, "Technology Fellow", and Pacemaker Business in Greater ChinaBU Head, once led or participated as a major contributor in numerous pacemaker/The research and development and global launch of innovative products for heart failure, including5One was a groundbreaking, world-first product and therapy in the industry at the time. He served as the first leader of United InnoMed, a leading domestic medical device company.CEO, leading the team to achieve the first“International Quality, Made in China”The domestically produced cardiac pacemaker has been launched for commercial sale and listed by the Ministry of Science and Technology.2018"Innovative Medical Device Product Catalog" of the year. Dr. Wang Li assisted the association and top experts in innovatively proposing and promoting globally.1.5The concept of level prevention has greatly accelerated in China.ICDThe promotion of new therapies and their inclusion2021Year ChinaICDExpert Consensus.

Dr. Wang Li is a member of the American Heart Rhythm SocietyHRSAcademician (Fellow of HRS), has won2014Annual "Outstanding Contribution Award" from the Chinese Medical Association's Branch of Electrophysiology and Pacing, successively elected as the Vice Chairman of the National Active Implantable Devices Subcommittee, Chairman of the Medical Device Professional Committee of the Shanghai Pudong New Area Biomedical Industry Association, Director of the Shanghai Jiaotong University Medical Device Industry Alumni Association, Review Expert for the "Intelligent Creation Cup" Frontier Technology Challenge, Yangtze River DeltaG60Experts from the Sci-Tech Innovation Corridor Advisory Committee, etc.

The company has gathered a group of outstanding talents with rich experience, innovative thinking, and international perspectives in the field of Class III implantable medical devices (including sensors) development, covering backgrounds in quality, R&D, medicine, clinical, manufacturing, registration, and management. Among them,80%The above are R&D personnel,40%The above have master's and doctoral degrees, with core team management and R&D experience averaging over15Year.

The Lead Investor of This RoundMr. Yu Zhihua, Founding Partner of Longpan InvestmentRepresentation:Heart failure is the severe and end stage of various heart diseases, with a high incidence rate and a large patient base. With aging and the high prevalence of related chronic diseases, the number of heart failure patients will continue to grow, making it one of the most significant cardiovascular diseases today. Currently, clinical diagnosis and treatment methods for heart failure are relatively limited, leaving a relative clinical gap., The market demand is huge. The founding team of United InnoMed has30Years of innovative product R&D, clinical, and market promotion capabilities, focusing on urgent needs/Provide chronic heart failure patients with a "closed-loop" heart failure management solution. The product line is relatively complete, and the products are uniquely innovative with extremely high technical barriers. Longpan Investment is delighted to cooperate with United InnoMed, and we look forward to United InnoMed's early development of effective and low-cost products that will benefit a large number of heart failure patients.

This round's lead investorMr. Huang Ning, Founding Partner of Daotong InvestmentRepresentation:With the accelerating trend of population aging, heart failure, as the endpoint of cardiovascular diseases, affects a large number of patients and imposes a significant social burden. The mortality and readmission rates of heart failure patients remain high, with expensive treatment costs. There is a substantial market demand for long-term effective management concepts and methods for heart failure patients. However, there are few device-based therapies for heart failure, and there is an urgent need for innovative technologies to promote cost-effective treatments and increase their adoption. We have high expectations for the United InnoMed team, whose founder has deep expertise in active implants and the field of heart failure.30For many years, and possesses highly mature experience in product development and commercialization. Based on a profound understanding of the mechanisms of heart failure, the company has built a globally innovative product pipeline, being the first to strategically develop products with both therapeutic and diagnostic functions for chronic heart failure on a global scale. At the same time, it innovatively designs device-based treatment solutions for acute heart failure, addressing a significant clinical gap in this treatment area, truly realizing a "closed-loop" model for heart failure management and providing a comprehensive solution.